TIGIT and neoplasm: In addition, TIGIT has been found to bind three ligands, namely CD155 (PVR), CD112 (PVRL2, nectin-2), and CD113 (PVRL3), which are expressed by tumor cells, antigen-presenting cells, and also T-lymphocytes in the tumor microenvironment [95,96,97].